Rigel Pharmaceuticals has launched VEPPANU (vepdegestrant), the first FDA-approved PROTAC drug, in the US for adults with advanced or metastatic ER+/HER2-, ESR1-mutated breast cancer after progression on endocrine therapy. VEPPANU offers a novel treatment mechanism by degrading disease-causing proteins and showed significant improvement in progression-free survival in trials. It is available by prescription at $29,400 per month, with patient support programs to assist access. This launch marks a key advancement in treatment options for this breast cancer subtype and supports Rigel's growth strategy.
Robo.ai Inc. reported a turnaround in its financials for the first half of 2026, shifting from a $116.1 million shareholders' deficit to $95.8 million in positive equity. This improvement followed the disposal of its legacy business and acquisitions ...
SU Group's subsidiary Shine Union Macao secured exclusive rights to market and sell the Inspec Spider, an award-winning robotic high-mast inspection system, in Macao. This partnership enhances SU Group's technology offerings and supports its expansio...
Claims that XRP could be used with the Federal Reserve's FedNow payment system through Volante Technologies have sparked excitement in the XRP community. Volante connects financial institutions to multiple payment rails including FedNow and has a lon...
Dogecoin (DOGE) is trading at $0.09272 with a 2.74% gain and a $15.8 billion market cap, showing signs of a potential bullish reversal through a weekly double-bottom chart pattern. Traders watch the key $0.40 neckline level, which if broken, could si...
Bitcoin jumped from around $64,330 to $74,440 last week, marking a 23.23% weekly gain after months of decline and stagnation. This surge, predicted by analysts in early August, signals a potential new bull market similar to past recoveries in 2019 an...
